Harnessing The Full Potential of Cell Therapy
Inceptor Bio is Pioneering Next-Generation CAR-M Therapies to Cure Solid Tumors
Our Singular Focus:
To Advance Cell Therapies To Cure Cancer
Inceptor Bio is committed to confronting one of humanity’s single most complex problems — solid tumor cancers. Every day, we are working to develop and deliver therapies that have the potential to cure patients.
CAR-M: Pioneering a New Modality
At Inceptor Bio, we’re transforming immunotherapy with our cutting-edge CAR-M platform. Our approach integrates proprietary technology that improves the mechanism of action for CAR-M: infiltration, eradication, and orchestration.
Infiltrate
CAR-M infiltrate deep into solid tumors, navigate through complex stroma, and overcome physical barriers to precisely deliver targeted therapies
Eradicate
CAR-M increase phagocytosis of tumor cells, eliminating cancer through targeted engulfment
Orchestrate
CAR-M orchestrate immune responses, coordinate with other immune cells, and enhance anti-tumor immunity in the tumor microenvironment
Stay Up to Date on Inceptor
Inceptor Bio Appoints Matthias Schroff, PhD, as Chief Executive Officer
Morrisville, NC – Inceptor Bio, a biotechnology company advancing cell therapies for difficult-to-treat cancers, announced the appointment of Dr. Matthias Schroff as
Ori Biotech and Inceptor Bio Partner to Accelerate Solid tumor Cell Therapy Access
Inceptor joins Ori’s LightSpeed Early Access Program (LEAP) to future proof manufacturing capabilities, ahead of its first clinical trials in
Inceptor Bio and Avectas Announce Collaboration to Improve Manufacturing of CAR-T Cell Therapies for the Treatment of Solid Tumors
Inceptor Bio, a cell therapy biotechnology company and Avectas, a cell engineering technology leader, announce their collaboration to improve the development and manufacturing
